Voyager Therapeutics, Inc.

NASDAQ:VYGR

Biotechnology

Healthcare
$1.67 +2.35%

+$0.09 today

Market cap
$103.92M
Beta
1.25
P/E (TTM)
-1.9
EPS (TTM)
-$1.96
52W Low $2.83High $5.55

Volume 0.84M

Average 0.54M

VYGR Total Current Assets

All assets expected to be converted to cash or used up within one year.

Voyager Therapeutics, Inc.NASDAQ: VYGR

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets falls 40.1% from a year ago

Total current assets stood at $146.98M at the end of Q1 FY2026, down 40.1% from a year earlier and down 27.5% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.

Context

  • Total current assets amounted to 67.0% of total assets at the end of Q1 FY2026, down 2.4 pp from a year earlier.
  • Total current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether total current assets keeps falling in the next quarterly balance sheet after a -40.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$146.98M-27.5% QoQ
Last fiscal yearDec 2025
$202.69M-26.8% YoY
Year agoMar 2025
$245.21M-40.1% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.1%——
1 year-26.8%——
3-year CAGR+17.6%——
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
202.69M USD
Year-over-year change
-26.8%
4-year CAGR
+10.3%

Total Current Assets vs competitors

How VYGR compares with its peers on the latest reported figures

  • VYGR's Mar 2026 total current assets of $146.98M is the 7th highest of the 11 companies compared; the peer median is $197.65M.
  • Its year-over-year change of -40.1% is the 10th highest of 11, against a peer median of -26.4%.
  • Total current assets amounts to 67.0% of total assets for VYGR, versus a peer median of 75.2%.
VYGR Competitors Peer median
Total Current Assets for VYGR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VNDAVanda Pharmaceuticals Inc.Mar 2026$293.17M -28.1%-12.6%67.6%
ALLOAllogene Therapeutics, Inc.Mar 2026$273.29M -6.3%-21.3%69.0%
TRDAEntrada Therapeutics, Inc.Mar 2026$266.87M -33.8%+13.4%79.5%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$263.2M -39.3%-22.2%98.5%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$216.88M -22.2%-15.7%88.4%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$178.41M -26.5%-13.1%56.7%
VYGRVoyager Therapeutics, Inc.Mar 2026$146.98M -40.1%+17.6%67.0%
SGMTSagimet Biosciences Inc.Mar 2026$107.72M -26.3%+52.5%100.0%
HUMAHumacyte, Inc.Mar 2026$63.6M -13.7%-24.0%57.5%
PYXSPyxis Oncology, Inc.Mar 2026$45.57M -59.3%-27.2%70.9%
ACHVAchieve Life Sciences, Inc.Mar 2026$31.06M +24.2%+13.4%93.8%
Peer median (excluding VYGR) $197.65M-26.4%-14.4%75.2%

Competitors are the stored peer set for VYGR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents117.43M98.96M68.8M71.37M65.3M
Short-term Investments15.11M19.89M162.07M195.32M131.15M
Net Receivables748K639K84.46M4.49M1.76M
Inventory00000
Other Current Assets1.7M4.23M2.63M2.87M4.48M
Total Current Assets136.7M124.5M319.68M276.81M202.69M
Property, Plant & Equipment (Net)55.38M33.34M30M47.66M41.61M
Goodwill00000
Intangible Assets00000
Long-term Investments00065.7M0
Tax Assets00000
Other Non-current Assets1.78M1.52M1.59M2.87M7.98M
Total Non-current Assets57.16M34.86M31.6M116.24M49.59M
Total Assets193.86M159.36M351.28M393.05M252.28M
Account Payables574K2.57M1.6M4M5.01M
Short-term Debt00000
Tax Payables00000
Deferred Revenue33.89M59.38M42.88M24.39M1.59M
Other Current Liabilities5.02M4.56M6.61M6.75M9.09M
Total Current Liabilities50.98M72.59M64.51M49.79M26.54M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)8.21M6.45M32.36M6M0
Other Non-current Liabilities1M1M1M1M1M
Total Non-current Liabilities47.82M27.75M50.45M43.5M29.66M
Total Liabilities98.8M100.34M114.96M93.29M56.2M
Common Stock38K38K44K55K59K
Retained Earnings(347.1M)(393.51M)(261.18M)(326.18M)(445.91M)
Accumulated OCI(138K)(219K)(48K)(407K)32K
Other Stockholders Equity00000
Minority Interest00000
Total Equity95.06M59.02M236.32M299.76M196.08M
Total Debt44.18M23.13M20.29M43.73M36.5M
Net Debt(73.25M)(75.83M)(48.51M)(27.64M)(28.8M)

Voyager Therapeutics, Inc.

NASDAQ:VYGR

Intrinsic Alpha fair value

Locked

Current Price

$1.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.